环孢素治疗表皮坏死松解症的新证据
New Evidence Supporting Cyclosporine Efficacy in Epidermal Necrolysis.
PubMed 文献 · J Invest Dermatol · 2017-01-01
该文评论一项系统综述及Gonzales-Herrada等的研究,指出在专科对症支持治疗基础上,环孢素可能降低表皮坏死松解症(从Stevens-Johnson综合征到中毒性表皮坏死松解症)的死亡风险。
要点
- 环孢素可能降低表皮坏死松解症的死亡风险
- 证据来自一项系统综述及Gonzales-Herrada等的研究
- 专科对症支持治疗仍是基础,环孢素为其附加治疗
核心结论
- 环孢素在降低表皮坏死松解症死亡风险方面可能有效
主要发现
- 近期发表的系统综述与Gonzales-Herrada等的研究均强烈提示环孢素可降低死亡风险
临床怎么用
- 在专科机构中,除必要的对症治疗外,可考虑将环孢素用于表皮坏死松解症的治疗
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sixty years after its original description by Sir Alan Lyell, epidermal necrolysis (from Stevens-Johnson syndrome to toxic epidermal necrolysis) seems finally amenable to a specific treatment in addition to essential symptomatic measures in specialized settings. A recently published systematic review and an article by Gonzales-Herrada et al. strongly suggest that cyclosporine is effective in reducing the risk of death.
来源:J Invest Dermatol,查看原文。版权归原作者所有。
引用
- Roujeau JC, Mockenhaupt M, Guillaume JC, et al. New Evidence Supporting Cyclosporine Efficacy in Epidermal Necrolysis. J Invest Dermatol. 2017. PMID: 28941473. doi:10.1016/j.jid.2017.07.828
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。